Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT.
about
Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated CandidiasisDistinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic ModelingClinical population pharmacokinetics and toxicodynamics of linezolid.Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin.Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. ColistinA mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transportPharmacokinetic alteration of baclofen by multiple oral administration of herbal medicines in ratsComparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.Impact on resistance of the use of therapeutically equivalent generics: the case of ciprofloxacinComparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumanniiPopulation Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery.Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearanceMechanism-based model of parasite growth and dihydroartemisinin pharmacodynamics in murine malaria.Pharmacodynamic variability beyond that explained by MICs.Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing designOptimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosaAMGET, an R-Based Postprocessing Tool for ADAPT 5Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer.Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapyPopulation Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery.Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysisEven apparently insignificant chemical deviations among bioequivalent generic antibiotics can lead to therapeutic nonequivalence: the case of meropenem.Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers.p16INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects.Evaluation of enrofloxacin use in koalas (Phascolarctos cinereus) via population pharmacokinetics and Monte Carlo simulation.Pharmacokinetics of ertapenem in colorectal tissue.Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli.High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance.Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats. 4. Aztreonam.Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus.
P2860
Q27347943-9CC5776D-C444-4CDE-8DB5-7A2197EE5844Q28550711-699E526D-0285-4973-9D17-A75C897D02AFQ33413269-D110113F-57E5-46C9-99F8-676D55E3C101Q33798218-E42951A3-C87A-400F-A7B3-97BC2A490242Q33798554-B258C2C3-DD5E-451B-B258-4BCBDE28DF09Q34060125-CF90D3BB-846E-4577-885F-192DD077131CQ34501161-239BE6B0-BACD-496A-827A-88192F5A549FQ34597749-8188F6E7-8DD7-4EFC-8DE2-FAB26AF665C4Q34922857-B7E1F608-3A93-4718-9149-0349419803E5Q35005118-35451FA8-C561-4AA8-915D-186E71FBA8E7Q35168882-8DF37DF4-4C87-4B8A-BDED-3ECD8D32F0BCQ35168931-7065D535-BECF-456A-A00F-8BA6D4FE29E2Q35967888-336932F3-1E56-4D53-A37C-CFDFF016C03AQ36076101-B4BDC7EF-0AE3-493F-B357-B4744FA3A304Q36364174-47ADD8EB-FD16-4EA7-AB6F-5E26EC1B7B9FQ36430073-FB4FF025-EA86-46C1-92CB-5E2E0AAE9C8FQ36505360-49CD2255-0158-4A14-846D-540FC3598587Q36505504-C272411D-DCD3-4C05-B3E1-382C0F82D654Q36757639-5C77CC22-5915-4A9E-B0A3-1DDE2764686DQ36785827-94ADE55E-7176-494A-BD45-FF7FBD89353DQ36887819-7E8B10E4-0411-4838-9F89-D7C25B726A04Q37065410-FA3BB166-8976-458B-9F90-D48198624E71Q37100575-1A64C0D0-B5D9-48B5-8889-051831392B61Q37335282-CCE11465-B957-465D-AF1C-262502531BA9Q37538609-AF12A94D-459D-4E9E-AF9A-B6651D6469C7Q37538623-0C8426C7-654B-45A8-A626-AAAC38332B18Q37538748-F15E68F0-1B0E-4CE4-B952-727A09E936C2Q37544285-27001C20-4490-49DD-9F7D-CA066FE89F77Q37544589-EF3949EE-4179-40D8-BBF6-5285DF5918D5Q37660706-E6EB4378-091E-4E2A-864F-64CCC43C2B6FQ37660709-909CEE6B-B4C6-489B-9A2F-01DA65707742Q37845550-AEE6952B-7B46-4E00-9187-8D62BDA930C9Q38479091-E6D63751-618B-4905-BAEB-318B6672FF12Q38785797-56D0C16B-3C72-4C27-AC5A-5EBAA0199344Q39170967-71F095B2-CD1C-42C2-A3AD-94D42D129D2EQ40306198-069C95D7-E187-47B7-9722-F6AC31B4A12CQ40657200-D7F757DF-746D-4D58-A817-E065DDEAF08DQ40719307-5A334F1C-D27A-471A-AAE7-303516DE40E4Q41284108-7AC1C585-2DC6-4B60-8166-4E23C2DB6B18Q42110580-EB766C8B-562D-4006-8609-ABC602B1FD92
P2860
Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Development of a new pre- and ...... d-effects modeling in S-ADAPT.
@en
type
label
Development of a new pre- and ...... d-effects modeling in S-ADAPT.
@en
prefLabel
Development of a new pre- and ...... d-effects modeling in S-ADAPT.
@en
P2093
P2860
P1433
P1476
Development of a new pre- and ...... d-effects modeling in S-ADAPT.
@en
P2093
Ayhan Bingölbali
Beom Soo Shin
Jurgen Bernd Bulitta
P2860
P2888
P304
P356
10.1208/S12248-011-9257-X
P407
P577
2011-03-03T00:00:00Z
P5875
P6179
1052527421